Literature DB >> 29171729

Long-term outcomes in unilateral vocal fold paralysis patients.

Conor W McLaughlin1, Brian Swendseid2, Mark S Courey3, Sarah Schneider1, Jackie L Gartner-Schmidt4, Katherine C Yung1.   

Abstract

OBJECTIVES/HYPOTHESIS: At presentation, unilateral vocal fold paralysis (UVFP) patients have different treatment options, including conservative management (CM), injection laryngoplasty (IL) with a temporary agent, or permanent medialization (PM). This study evaluates long-term outcomes for UVFP patients relative to intervention. STUDY
DESIGN: Retrospective chart review.
METHODS: A retrospective chart review was performed of UVFP patients who presented to the University of California San Francisco Voice and Swallowing Center. Videolaryngostroboscopy examinations were reviewed. Maximum glottic closure was quantified with the normalized glottic gap area (NGGA). Perceptual voice analysis was performed using the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) at corresponding time points.
RESULTS: Fifty-three patients met inclusion criteria. Six underwent CM only, 20 went on to require PM, 19 underwent IL only, and eight underwent IL and subsequent PM. NGGA at presentation was similar among groups; however, the CM group was noted to have more favorable CAPE-V scores for Breathiness (P = .007) and Loudness (P = .018). All groups had similar NGGA and CAPE-V scores at last follow-up. When compared to pooled data for patients who underwent PM, the IL group was noted to have similar NGGA and CAPE-V scores at presentation. Although improvements in both groups were noted following intervention, both groups appeared similar at last follow-up with the exception of Roughness, for which the IL group retained a slightly improved outcome (13.3 vs. 18.3, P = .03).
CONCLUSIONS: At presentation, UVFP patients have similar NGGA. This finding suggests that treatment recommendations cannot be made on the size of the glottic gap alone. Furthermore, in many patients, IL results in long-term benefit with glottic closure and CAPE-V scores equivalent to that obtained with PM. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:430-436, 2018.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Vocal fold paralysis; injection laryngoplasty; type I thyroplasty

Mesh:

Year:  2017        PMID: 29171729     DOI: 10.1002/lary.26900

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  The surgical treatment of unilateral vocal cord paralysis (UVCP): qualitative review analysis and meta-analysis study.

Authors:  F Granato; F Martelli; L V Comini; P Luparello; S Coscarelli; O Le Seac; S Carucci; P Graziani; R Santoro; G Alderotti; M R Barillari; Giuditta Mannelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-08-02       Impact factor: 2.503

2.  Thyroplasty in unilateral vocal fold paresis with coexisting hereditary hemorrhagic telenagiectasia: A case report.

Authors:  Joanna Jackowska; Hanna Klimza; Natalia Zagozda; Marc Remacle; Waldemar Wojnowski; Krzysztof Piersiala; Małgorzata Wierzbicka
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

3.  Can preoperative results predict the need for future reintervention following injection laryngoplasty for unilateral vocal fold paralysis?

Authors:  Beata Miaśkiewicz; Aleksandra Panasiewicz; Elżbieta Gos; Paulina Krasnodębska; Piotr H Skarżyński; Agata Szkiełkowska
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-06-09       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.